Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Ovarian Neoplasms

Free Subscription 12.11.2018 1 Am J Clin Pathol 1 BMC Cancer 1 Cancer Res 7 Gynecol Oncol 1 Lancet Oncol 1 Obstet Gynecol

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Am J Clin Pathol

1. NISHIKIMI K, Nakagawa K, Tate S, Matsuoka A, et al
   Uncommon Human Telomerase Reverse Transcriptase Promoter Mutations Are Associated With Poor Survival in Ovarian Clear Cell Carcinoma.
   Am J Clin Pathol. 2018;149:352-361.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

2. YOSHIMURA A, Sawada K, Nakamura K, Kinose Y, et al
   Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells.
   BMC Cancer. 2018;18:1065.
   PubMed     Text format     Abstract available
   
   

   
   Cancer Res

3. LU Y, Hu Z, Mangala LS, Stine ZE, et al
   MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels.
   Cancer Res. 2018;78:64-74.
   PubMed     Text format     Abstract available
   
   

   
   Gynecol Oncol

4. MATSUOKA A, Tate S, Nishikimi K, Shozu M, et al
   Successful retroperitoneal lymphadenectomy for double inferior vena cava with preoperative assessment using contrast-enhanced and three-dimensional computed tomography.
   Gynecol Oncol. 2018;151:180-181.
   PubMed     Text format    
   
   
5. PERES LC, Cushing-Haugen KL, Anglesio M, Wicklund K, et al
   Histotype classification of ovarian carcinoma: A comparison of approaches.
   Gynecol Oncol. 2018 Aug 15. pii: S0090-8258(18)31133.
   PubMed     Text format     Abstract available
   
   
6. LYCKE M, Kristjansdottir B, Sundfeldt K
   A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
   Gynecol Oncol. 2018 Aug 24. pii: S0090-8258(18)31155.
   PubMed     Text format     Abstract available
   
   
7. VAN NIEUWENHUYSEN E, Busschaert P, Neven P, Han SN, et al
   The genetic landscape of 87 ovarian germ cell tumors.
   Gynecol Oncol. 2018 Aug 28. pii: S0090-8258(18)31130.
   PubMed     Text format     Abstract available
   
   
8. MULLEN MM, Kuroki LM, Thaker PH
   Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review.
   Gynecol Oncol. 2018 Nov 5. pii: S0090-8258(18)31306.
   PubMed     Text format     Abstract available
   
   
9. LEE JY, Park JY, Park SY, Lee JW, et al
   Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041).
   Gynecol Oncol. 2018 Nov 5. pii: S0090-8258(18)31314.
   PubMed     Text format     Abstract available
   
   
10. ZHONG Q, Hu Z, Li Q, Yi T, et al
    Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib.
    Gynecol Oncol. 2018 Nov 7. pii: S0090-8258(18)31310.
    PubMed     Text format     Abstract available
    
    

    
    Lancet Oncol

11. FAGOTTI A, Scambia G
    Neoadjuvant chemotherapy versus upfront debulking surgery in advanced tubo-ovarian cancer.
    Lancet Oncol. 2018 Nov 6. pii: S1470-2045(18)30625.
    PubMed     Text format    
    
    

    
    Obstet Gynecol

12. WRIGHT JD
    What Is New in Ovarian Cancer?: Best Articles From the Past Year.
    Obstet Gynecol. 2018 Nov 5. doi: 10.1097/AOG.0000000000002989.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: